Aug 29, 2025
FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease
Jul 30, 2025
New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains
Jul 28, 2025
Next Era of Alzheimer's Care Will be Defined by Precision Prevention
Jun 02, 2025
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Invests in Expansion of Quality Control Program for Blood and CSF Biomarkers
May 16, 2025
Statement from the Alzheimer's Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer's Diagnosis
Apr 24, 2025
Alzheimer's Drug Discovery Foundation Chief Executive Officer Mark Roithmayr Announces Retirement in 2025
Mar 12, 2025
The ADDF's Diagnostics Accelerator Authors New Paper on Ocular Biomarker Landscape, Highlighting Ocular Tests as a Tool for Early Detection of Alzheimer's Disease
Jan 08, 2025
Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer's Disease
Nov 14, 2024
New Investment from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
Oct 07, 2024
New Considerations for Accelerating Combination Therapy Trials to be Showcased at 2024 Clinical Trials on Alzheimer's Disease Conference
Sep 25, 2024
Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics' Blood Tests
Sep 18, 2024
Alzheimer's Drug Discovery Foundation Invests in First-of-its-Kind Biomarker Observatory Led by Renowned Clinical Trials Expert to Accelerate Novel Drug Development
Sep 12, 2024
ADDF Marks Tenth Anniversary of Melvin R. Goodes Prize with Celebration in Stockholm, Sweden, Honoring Scientists Dedicated to Innovation in Alzheimer's Research
Jul 02, 2024
ALZHEIMER'S DRUG DISCOVERY FOUNDATION (ADDF) STATEMENT ON FDA'S TRADITIONAL APPROVAL OF KISUNLA (DONANEMAB)
Jun 10, 2024
ALZHEIMER'S DRUG DISCOVERY FOUNDATION'S (ADDF) STATEMENT ON FDA ADVISORY COMMITTEE'S ENDORSEMENT OF DONANEMAB
May 17, 2024
New Study in Nature Medicine Shows Novel Neuroprotective Drug Candidate Meets Primary Endpoint in Patients with Mild to Moderate Alzheimer's Disease
May 13, 2024
Alzheimer's Drug Discovery Foundation (ADDF) and Association for Frontotemporal Degeneration (AFTD) Extend Treat FTD Fund Through 2035
Apr 01, 2024
Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2024 ADDF-Harrington Scholar Award
Mar 08, 2024
Alzheimer's Drug Discovery Foundation (ADDF) Statement on FDA Decision to Convene Advisory Committee for Donanemab
Dec 15, 2020
The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration Invite Proposals for 2021 Treat FTD Fund